Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy

doi:10.3748/wjg.v27.i11.1101

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 27, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6964)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-3) series.

Item

Count

PDF

407

WORD

154

HTML

3273

Figures (1-4)

349

Tables (1-3)

219

Sum=4402

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

565

Download

761

Sum=1326

Publishing Process of This Article

Item

Count

Browse

400

Download

836

Sum=1236

Mar 21, 2021 (publication date) through Apr 23, 2024

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Gastroenterol. Mar 21, 2021; 27(11): 1101-1116
Published online Mar 21, 2021. doi: 10.3748/wjg.v27.i11.1101

Open in New Tab Full Size Figure Download Figure

Figure 1 Flow chart of the control group.

Open in New Tab Full Size Figure Download Figure

Figure 2 Cumulative incidence of hepatocellular carcinoma. A: Comparison of the incidence of hepatocellular carcinoma over time in two groups of chronic hepatitis B patients (patients with liver protection and anti-inflammatory treatment and patients with antiviral therapy); B: Comparison of the incidence of hepatocellular carcinoma over time in patients with hepatitis B cirrhosis. HCC: Hepatocellular carcinoma.

Open in New Tab Full Size Figure Download Figure

Figure 3 Cumulative incidence of hepatocellular carcinoma. A: Incidence of hepatocellular carcinoma after hepatitis B e antigen negative conversion in hepatitis B e antigen-positive chronic hepatitis B patients; B: Cumulative incidence of hepatocellular carcinoma after hepatitis B virus-DNA negative conversion in patients with chronic hepatitis B. HCC: Hepatocellular carcinoma; HBeAg: Hepatitis B e antigen; HBV: Hepatitis B virus.

Open in New Tab Full Size Figure Download Figure

Figure 4 Cumulative incidence of hepatocellular carcinoma. A: Cumulative incidence of hepatocellular carcinoma in patients with antiviral resistance in chronic hepatitis B; B: Cumulative incidence of hepatocellular carcinoma in patients with antiviral resistance in hepatitis B cirrhosis. HCC: Hepatocellular carcinoma.

Citation: Jiang XY, Huang B, Huang DP, Wei CS, Zhong WC, Peng DT, Huang FR, Tong GD. Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy. World J Gastroenterol 2021; 27(11): 1101-1116
URL: https://www.wjgnet.com/1007-9327/full/v27/i11/1101.htm
DOI: https://dx.doi.org/10.3748/wjg.v27.i11.1101